Q-omics provides the consensus-scored CD24 profile across patient tissues and cancer cell-line models. CD24 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CD24 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CD24 RNA expression shows 17,210 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, HNSC, and KIRP as cancer lineages where CD24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD24 survival associations across molecular data types. CD24 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD24 RNA expression–survival associations across cancer types. High CD24 expression shows unfavorable associations in MESO, BRCA and LIHC, but favorable associations in KIRC, LGG and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CD24 RNA expression.
This table summarizes CD24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CD24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD24 shows lower tumor expression in HNSC, THCA, COAD and KICH and higher tumor expression in LUAD and BLCA. The HNSC box plot shows higher CD24 RNA expression in normal versus tumor tissue (log2 FC = −1.588, t-test p < 0.001).
This table shows molecular features associated with CD24 in patient tissues and cancer cell lines. In patient samples, CD24 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CD24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
